PRESCRIBING · PART D · 2024
Total Rx claims
136
Beneficiaries
—
Total drug cost
$1.6M
Distinct drugs
7
Brand share
72.1%
Top prescribed drugs
Ruxolitinib Phosphate46 claims
Hydroxyurea26 claims
Apixaban14 claims
Fedratinib Dihydrochloride14 claims
Nilotinib Hcl13 claims
QUALITY · MIPS · 2024
Final MIPS score
87.5
Quality
79.4
Cost
73.7
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.53%
Group
CROSS-REFERENCE